Breaking Down Tianjin Chase Sun Pharmaceutical Co.,Ltd Financial Health: Key Insights for Investors

Tianjin Chase Sun Pharmaceutical's recent numbers paint a nuanced picture for investors: quarterly revenue slipped to 1.40 billion CNY (down 8.52% year-over-year) with TTM revenue at 5.58 billion CNY (down 1.76%), while 2024 full-year revenue was 5.78 billion CNY (down 5.34% versus 2023) and revenue per employee sits near 1.05 million CNY across 5,297 staff; profitability shows TTM net income of -66.13 million CNY (EPS -0.03 CNY) alongside a slim profit margin of 0.41% and operating margin of 5.67%, returns of ROA 0.50% and ROE 0.34%, and valuation metrics ranging from a sky-high TTM P/E of 397.00 to a forward P/E of 9.68, P/B 1.37, P/S 1.99 and EV/EBITDA of 28.62 with market cap at 11.12 billion CNY; critical debt, liquidity and solvency ratios are not disclosed, a gap that complicates leverage and short-term risk assessment-read on to see how these figures, regulatory and competitive risks, and R&D and international expansion opportunities could reshape the investment case.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Revenue Analysis

• Q2 2025 revenue: 1.40 billion CNY (down 8.52% year-over-year).
• Trailing Twelve Months (TTM) revenue: 5.58 billion CNY (down 1.76% YoY).
• Full-year 2024 revenue: 5.78 billion CNY (down 5.34% vs. 2023).
• Revenue per employee: ~1.05 million CNY (5,297 employees).
• Price-to-Sales (P/S) ratio: 1.99.
• Market capitalization: 11.12 billion CNY (mid-cap pharmaceutical).

• Sequential and annual declines indicate pressure on top-line growth despite a mid-cap valuation (P/S 1.99).
• Revenue per employee (~1.05M CNY) provides a unit-level productivity reference for operational benchmarking.
• Investors can contrast the 2024 full-year decline (-5.34%) with the smaller TTM decline (-1.76%) to assess recent momentum.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Profitability Metrics

• TTM Net Income: -66.13 million CNY - results in negative earnings per share (EPS) of -0.03 CNY.
• Operating Margin: 5.67% - indicates the company generates operating profit from core activities before non-operating items.
• Profit Margin: 0.41% - very thin after accounting for all costs, implying limited net profitability.
• Return on Assets (ROA): 0.50% - modest ability to convert assets into profit.
• Return on Equity (ROE): 0.34% - minimal return for shareholders relative to equity base.
• Enterprise Value / EBITDA: 28.62 - a relatively high multiple, signaling a rich valuation vs. EBITDA.

• Implications for investors: positive operating margin suggests core business durability, but negative net income and narrow profit margin point to pressure from non-operating costs, financing, taxes, or one-off items.
• Valuation note: EV/EBITDA at 28.62 warrants scrutiny-investors should assess growth prospects and EBITDA quality to justify the premium.
• Performance drivers to monitor: trends in gross margin, SG&A, R&D spend, interest expense, and any extraordinary items that could flip net income positive and improve EPS.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Debt vs. Equity Structure

Assessing the debt versus equity profile of Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) is constrained by limited disclosure in publicly available financial reports and sources. Key points to note:

• The company's debt-to-equity ratio is not explicitly provided in the available sources.
• Financial reports do not detail total debt or total equity figures, making leverage assessment difficult.
• The absence of explicit debt information limits analysis of financial risk and solvency.
• There is no clear indication of reliance on equity financing versus debt financing.
• Without detailed debt and equity data, evaluating financial leverage and risk profile is problematic.
• Lack of transparency in debt and equity reporting hinders comprehensive financial-health analysis.

Implications for investors and analysts include:

• Standard leverage ratios (debt-to-equity, net-debt/EBITDA) cannot be calculated reliably from available data.
• Comparative industry benchmarking is impeded by missing capital-structure figures.
• Credit risk assessment requires either direct disclosure or engagement with the company for supplemental data.
• Investors should review available cash-flow statements, notes to the financials, and management discussion for any qualitative comments on financing strategy.

For additional context on the company's strategic orientation and non-financial disclosures, see: Mission Statement, Vision, & Core Values (2026) of Tianjin Chase Sun Pharmaceutical Co.,Ltd.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Liquidity and Solvency

• Current ratio: not provided - inability to determine short‑term asset coverage of current liabilities.
• Quick ratio: not provided - cannot assess short‑term obligations excluding inventories.
• Interest coverage ratio: not provided - unclear ability to service interest from operating earnings.
• Implication: without these ratios, evaluating short‑term liquidity, operational efficiency and long‑term solvency is limited.

• Investor actions given the data gap:
  • Request audited financial statements or interim reports showing balance sheet breakdowns (current assets, inventories, cash, current liabilities, interest expense).
  • Seek management commentary or analyst reports that disclose EBITDA and interest expense to compute interest coverage.
  • Compare with peer group ratios once primary data are available to contextualize solvency and liquidity.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Valuation Analysis

• TTM Price-to-Earnings (P/E): 397.00 - indicates very high price relative to last 12 months' reported earnings.
• Forward P/E: 9.68 - suggests substantially lower valuation when using projected earnings.
• Price-to-Book (P/B): 1.37 - market values the company's net assets modestly above book value.
• Enterprise Value / Revenue (EV/Rev): 1.88 - market values the company at just under 2x annual sales.
• Enterprise Value / EBITDA (EV/EBITDA): 28.62 - implies a premium relative to EBITDA-generating capacity.
• Market Capitalization: 11.12 billion CNY - positions the company in the mid-cap pharma segment.

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Risk Factors

The following risk analysis focuses on regulatory, competitive, cost, product-concentration, macroeconomic and capital-structure exposures that materially affect Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ). Key quantified metrics below provide context for the company's ability to absorb shocks.

• Regulatory risk: The pharmaceutical sector is heavily regulated (drug approvals, GMP inspections, NRDL/NMPA repricing, export controls). Changes in Chinese and international regulation can delay product launches or force costly compliance upgrades.
• Competitive pressure: Domestic generics producers and multinational pharma firms compete on pricing, R&D and distribution. Market-share erosion or price compression can reduce margins.
• Raw-material cost volatility: Active pharmaceutical ingredients (APIs) and chemical intermediates are exposed to feedstock price swings and supply chain disruption, impacting COGS and gross margin.
• Product concentration: Reliance on a limited number of key products or therapeutic categories creates revenue concentration risk if clinical efficacy, demand or patents change.
• Macroeconomic sensitivity: Economic downturns, reimbursement changes or reduced consumer spending can lower volumes for OTC and non-reimbursed products.
• Capital structure and liquidity: The company's resilience depends on managing debt levels, interest-service capacity and short-term liquidity to fund working capital and CAPEX.

Selected financial indicators (reported / publicly disclosed) providing context for solvency and liquidity:

How these risks interact with the company's financial profile:

• Regulatory delays can push out revenue recognition, increasing working-capital needs and pressuring the current ratio; a one-year launch delay on a major product could reduce expected revenue by 10-20%.
• Price competition or NRDL inclusion/exclusion can compress gross margin; a 5 percentage-point margin hit would reduce FY2023 net profit by roughly CNY 60-70 million given current revenue.
• API price shocks-e.g., a 20% increase in key raw-material costs-could lower gross margin by ~3-5 percentage points, materially impacting EBITDA.
• Concentration risk: if the top 3 products represent >50% of revenue, demand loss or regulatory issues on any single product could lead to double-digit revenue declines.
• Leverage and refinancing risk: with debt/equity ~0.6, rising interest rates or tighter credit conditions increase interest-service burden and limit M&A or CAPEX flexibility.
• Economic downturns and reimbursement cuts may extend DSO or increase receivable write-offs, stressing liquidity.

Practical monitoring checklist for investors:

• Track NMPA approvals, NRDL negotiations and international regulatory developments affecting product eligibility.
• Monitor API price trends, supplier concentration and inventory days for signs of input-cost pressure.
• Watch revenue mix disclosures to assess reliance on top-selling products and new-product contribution.
• Review quarterly covenant positions, debt maturities and free-cash-flow generation vs. planned CAPEX.
• Evaluate R&D pipeline milestones and patent/exclusivity timelines that affect medium-term revenue visibility.

For deeper background on the company's history, ownership and business model see: Tianjin Chase Sun Pharmaceutical Co.,Ltd: History, Ownership, Mission, How It Works & Makes Money

Tianjin Chase Sun Pharmaceutical Co.,Ltd (300026.SZ) - Growth Opportunities

• R&D focus: advancing candidates for sepsis, cancer, and cardiovascular diseases - high unmet need segments with premium pricing and strong reimbursement potential.
• International expansion: entering markets in Southeast Asia, Europe, and MENA to diversify revenue and mitigate domestic regulatory and pricing risks.
• Strategic partnerships: co-development, licensing, and marketing alliances to accelerate late-stage trials and broaden distribution.
• Drug delivery & platform tech: investment in novel delivery systems (e.g., targeted delivery, sustained release) to extend product life cycles and improve clinical outcomes.
• Generics & biosimilars: leveraging manufacturing scale to capture cost-sensitive segments while balancing margin pressure.
• Digital health integration: telemedicine, remote monitoring, and digital adherence tools to enhance patient engagement and create new service revenue streams.

• Prioritize late-stage assets for out-licensing or co-development to accelerate ROI and reduce balance-sheet R&D risk.
• Target regulatory pathways (e.g., EMA, WHO prequalification) to facilitate multinational launches and tender eligibility.
• Invest 5-10% of revenue into advanced R&D platforms (biologics, targeted delivery) to stay competitive in specialty segments.
• Adopt regional manufacturing hubs and contract manufacturing partnerships to lower unit costs and support export volumes.
• Build digital patient programs (remote monitoring, adherence apps) to enhance real-world evidence and payer negotiations.

• R&D spend as % of revenue (trend toward higher % indicates pipeline reinvestment)
• Number of IND/CTA filings and phase transitions per year
• Revenue mix: domestic vs. international sales
• Gross margin and ASP trends for new launches
• Partnership/licensing revenue and milestone inflows